<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831567</url>
  </required_header>
  <id_info>
    <org_study_id>3025/20</org_study_id>
    <nct_id>NCT04831567</nct_id>
  </id_info>
  <brief_title>Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors</brief_title>
  <acronym>MIBNET</acronym>
  <official_title>Phase II Study of MIBG-I131 (Metaiodobenzylguanidine) in Patients With Well Differentiated Neuroendocrine Tumors and MIBG Positive Scan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Camargo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AC Camargo Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic&#xD;
      metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated&#xD;
      neuroendocrine tumors and radiological progression or intolerance after standard lines of&#xD;
      treatment and with MIBG positive scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuroendocrine tumors (NET) are rare neoplasms, which frequently present metastatic and&#xD;
      incurable at diagnosis. In this context, few effective therapies exist. When the disease&#xD;
      becomes refractory to standard therapies, treatments with limited efficacy (eg, surgical&#xD;
      debulking, cytotoxic chemotherapies, interferon alpha) that could lead to important adverse&#xD;
      events are used. Therefore, clinical studies that test new therapeutic strategies in NET&#xD;
      patients with refractory disease are needed. Treatment with radiopharmaceuticals have been&#xD;
      studied in NET and showed to be promisor. As an example, is the treatment with Lutetium177&#xD;
      octreotate, disponible in Brazil for decades, and one of the most active therapeutic options&#xD;
      to NET.&#xD;
&#xD;
      The radiopharmaceutical MIBG-I131 (metaiodobenzylguanidine linked to Iodine131) is the first&#xD;
      treatment choice for patients with paraganglioma/pheochromocytoma (PggF), a rare type of&#xD;
      neuroendocrine neoplasm originated from neural ganglia. Patients with this neoplasia are&#xD;
      submitted to scintigraphy with MIBG-I131, a norepinephrine analog whose transporter protein&#xD;
      is highly expressed in this tumor. If the uptake is positive, patients receive treatment with&#xD;
      therapeutic doses of MIBG-I131. The disease control with this intervention could last two&#xD;
      years. Old and small studies suggested that MIBG-I131 could also have an activity in other&#xD;
      NET besides PggF. Gastrointestinal (GI) or lung NET could have a positive expression on&#xD;
      MIBG-I131 scan in up to 50% of the cases. With this rationale, retrospective series reported&#xD;
      that MIBG-I131 could offer clinical benefit in patients with GI NET, with disease control in&#xD;
      up to 80% of the cases. However, the literature regarding therapeutic MIBG-I131 to NET not&#xD;
      PggF is scarce, heterogeneous regarding population, methods of response assessment, doses of&#xD;
      the radiopharmaceutical, and short follow-up time. Therefore, due to the absence of effective&#xD;
      therapeutic options for patients with metastatic well-differentiated NET refractory to&#xD;
      standard treatments, the evidence that NET can have a positive expression on MIBG-I131 scan,&#xD;
      and that small retrospective studies with a low level of evidence suggest a benefit for&#xD;
      control disease and improvement of symptoms, the investigators proposed a phase II study of&#xD;
      MIBG-I131 to well-differentiated GI or lung NET patients with positive MIBG-I131 scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated neuroendocrine tumors and radiological progression or intolerance after standard lines of treatment and with MIBG positive scan.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR) at 6 months after the end of treatment</measure>
    <time_frame>At 6 months after the end of MIBG-I131 (4 cycles - each cycle is 60 days)</time_frame>
    <description>Defined by absence of radiological progression in conventional imaging examinations by RECIST 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measured by questionnaire</measure>
    <time_frame>At 6 months after the end of MIBG-I131 (4 cycles - each cycle is 60 days)</time_frame>
    <description>Quality of life questionnaire (QLQ), assessed by the European Organisation for Research and Treatment of Cancer Quality of Life for Neuroendocrine Tumors (EORTC QLQ-GINET21) (score ranging from 0 to 100, with higher scores meaning better state of the patient). Improvement in at least 10% of the baseline score will be considered positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) at 3 months after the end of treatment</measure>
    <time_frame>At 3 months after the end of MIBG-I131 (4 cycles - each cycle is 60 days)</time_frame>
    <description>Defined by absence of radiological progression in conventional imaging examinations by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Trough study completion, an average of 3 years</time_frame>
    <description>Defined by time from day 1 cycle 1 to death from any cause or radiological progression by RECIST 1.1, whichever occurs first. Patients alive and without progression at the time of study analysis will be censored for time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rate</measure>
    <time_frame>Trough study completion, an average of 3 years</time_frame>
    <description>Assessed by RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Biochemical response</measure>
    <time_frame>Trough study completion, an average of 3 years</time_frame>
    <description>Defined by at least 30 percent drop in the tumor marker (24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) and/or specific hormone), if functioning syndrome, at any time of treatment in relation to pre-treatment value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by questionnaires</measure>
    <time_frame>Trough study completion, an average of 3 years</time_frame>
    <description>Quality of life questionnaire (QLQ), assessed by the European Organisation for Research and Treatment of Cancer Quality of Life for Neuroendocrine Tumors (EORTC QLQ-GINET21) (score ranging from 0 to 100, with higher scores meaning better state of the patient). Improvement in at least 10% of the baseline score will be considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events assessed by Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Trough study completion, an average of 3 years</time_frame>
    <description>Frequency of adverse events of grades 2 or more by CTCAE version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MIBG-I131</intervention_name>
    <description>Radiopharmaceutical</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Histological diagnosis of well-differentiated neuroendocrine tumor (NET) (typical and&#xD;
             atypical lung carcinoids and NET of all gastroenteropancreatic sites according to&#xD;
             World Health Organization (WHO) 2019 classification); metastatic/unresectable, with no&#xD;
             possibility of curative treatment.&#xD;
&#xD;
          -  MIBG-I131 positive scan in at least one lesion with uptake compatible with therapeutic&#xD;
             effectiveness.&#xD;
&#xD;
          -  Disease with radiological progression (at least 10 percent tumor volume growth) in the&#xD;
             last 12 months before day 1 cycle 1.&#xD;
&#xD;
          -  Intolerance due to toxicities or lack of access to standard treatments - [private&#xD;
             context (somatostatin analog, everolimus) and public health system (somatostatin&#xD;
             analog)].&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance scale 0 to 2.&#xD;
&#xD;
          -  Adequate organic function as defined by the following criteria:&#xD;
&#xD;
               -  serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT) ≤&#xD;
                  2.5 times the upper limit of normal of the local laboratory (ULN-LL);&#xD;
&#xD;
               -  Total serum bilirubin ≤ 2.0 x ULN-LL;&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 / mm^3;&#xD;
&#xD;
               -  Platelet count ≥ 100,000 / mm^3;&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g / dL;&#xD;
&#xD;
               -  Estimated creatinine clearance by the Modification of Diet in Renal Disease&#xD;
                  (MDRD) equation ≥ 60ml / min&#xD;
&#xD;
          -  Term of free and informed consent signed by the patient or legal representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already treated with MIBG-I131.&#xD;
&#xD;
          -  A history of serious clinical or psychiatric illness that, by clinical judgment, may&#xD;
             involve participation risk in this study.&#xD;
&#xD;
          -  Patients participating in other protocols with experimental drugs.&#xD;
&#xD;
          -  Patients who underwent major recent surgery less than 4 weeks previously.&#xD;
&#xD;
          -  Patients receiving chemotherapy or other oncologic therapy for less than 3 weeks.&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Another synchronous neoplasm that requires systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel SP Riechelmann, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>AC Camargo Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel SP Riechelmann, Phd</last_name>
    <phone>+55 11 2180-5000</phone>
    <phone_ext>2779</phone_ext>
    <email>rachel.riechelmann@accamargo.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodrigo G Taboada, MD</last_name>
    <phone>+55 11 2180-5000</phone>
    <phone_ext>2779</phone_ext>
    <email>rodrigo.taboada@accamargo.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AC Camargo Cancer Center</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01509010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel SP Riechelmann, Phd</last_name>
      <phone>+55 11 2189-5000</phone>
      <phone_ext>2779</phone_ext>
      <email>rachel.riechelmann@accamargo.org.br</email>
    </contact>
    <contact_backup>
      <last_name>Rodrigo G Taboada, MD</last_name>
      <phone>+55 11 2189-5000</phone>
      <phone_ext>2779</phone_ext>
      <email>rodrigo.taboada@accamargo.org.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://qol.eortc.org/questionnaire/qlq-ginet21/</url>
    <description>EORTC Quality of Life Questionnaire - QLQ-GINET21</description>
  </link>
  <reference>
    <citation>Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.</citation>
    <PMID>19704057</PMID>
  </reference>
  <reference>
    <citation>Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.</citation>
    <PMID>28076709</PMID>
  </reference>
  <reference>
    <citation>Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.</citation>
    <PMID>28194228</PMID>
  </reference>
  <reference>
    <citation>van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501. doi: 10.1111/cen.12341. Epub 2013 Nov 19. Review.</citation>
    <PMID>24118038</PMID>
  </reference>
  <reference>
    <citation>Ezziddin S, Logvinski T, Yong-Hing C, Ahmadzadehfar H, Fischer HP, Palmedo H, Bucerius J, Reinhardt MJ, Biersack HJ. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006 Feb;47(2):223-33.</citation>
    <PMID>16455627</PMID>
  </reference>
  <reference>
    <citation>Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017 Feb;9(2):127-137. doi: 10.1177/1758834016675803. Epub 2016 Nov 2. Review.</citation>
    <PMID>28203303</PMID>
  </reference>
  <reference>
    <citation>Kane A, Thorpe MP, Morse MA, Howard BA, Oldan JD, Zhu J, Wong TZ, Petry NA, Reiman R Jr, Borges-Neto S. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with (131)I-MIBG. J Nucl Med. 2018 Nov;59(11):1708-1713. doi: 10.2967/jnumed.117.202150. Epub 2018 May 18.</citation>
    <PMID>29777005</PMID>
  </reference>
  <reference>
    <citation>Mulholland N, Chakravartty R, Devlin L, Kalogianni E, Corcoran B, Vivian G. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2002-12. doi: 10.1007/s00259-015-3116-4. Epub 2015 Jul 5.</citation>
    <PMID>26142730</PMID>
  </reference>
  <reference>
    <citation>Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010 May;37(5):904-12. doi: 10.1007/s00259-009-1326-3. Epub 2009 Dec 17.</citation>
    <PMID>20016892</PMID>
  </reference>
  <reference>
    <citation>Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003 Jun;15(4):193-8. Review.</citation>
    <PMID>12846498</PMID>
  </reference>
  <reference>
    <citation>Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D, Ramage JK; EORTC Quality of Life Group. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013 Feb 5;108(2):301-10. doi: 10.1038/bjc.2012.560. Epub 2013 Jan 15.</citation>
    <PMID>23322194</PMID>
  </reference>
  <reference>
    <citation>Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998 Jan;16(1):139-44.</citation>
    <PMID>9440735</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.</citation>
    <PMID>26703889</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AC Camargo Cancer Center</investigator_affiliation>
    <investigator_full_name>Rachel Riechelmann</investigator_full_name>
    <investigator_title>Head of Medical Oncology Department</investigator_title>
  </responsible_party>
  <keyword>MIBG-I131</keyword>
  <keyword>Nuclear medicine</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04831567/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04831567/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

